{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:30:35Z","timestamp":1791387035135,"version":"4.3.3"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.jaut.2015.11.002","type":"journal-article","created":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T06:43:46Z","timestamp":1450248226000},"page":"102-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"special_numbering":"C","title":["Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sj\u00f6gren's syndrome"],"prefix":"10.1016","volume":"67","author":[{"given":"Divi","family":"Cornec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Devauchelle-Pensec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Jousse-Joulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Marcorelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Berthelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Chiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hachulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"Hatron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Goeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Vittecoq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Saraux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Olivier","family":"Pers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2015.11.002_bib1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaut.2012.05.014","article-title":"B\u00a0cells in Sj\u00f6gren\u2019s syndrome: From pathophysiology to diagnosis and treatment","volume":"39","author":"Cornec","year":"2012","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.jaut.2015.11.002_bib2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of Primary Sj\u00f6gren Syndrome With RituximabA Randomized Trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann. Intern. Med."},{"issue":"9","key":"10.1016\/j.jaut.2015.11.002_bib3","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1093\/rheumatology\/kev114","article-title":"Development of the Sj\u00f6gren\u2019s Syndrome Responder Index (SSRI), a data-driven composite endpoint for assessing treatment efficacy","volume":"54","author":"Cornec","year":"2015","journal-title":"Rheumatology (Oxford)."},{"issue":"6","key":"10.1016\/j.jaut.2015.11.002_bib4","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/art.39088","article-title":"Ultrasonographic salivary gland response to rituximab in primary Sj\u00f6gren\u2019s syndrome","volume":"67","author":"Jousse-Joulin","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2015.11.002_bib5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/ard.2009.109041","article-title":"Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis","volume":"69","author":"Thurlings","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2015.11.002_bib6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/acr.22116","article-title":"Low-versus high-dose rituximab for Rheumatoid arthritis: a systematic review and meta-analysis","volume":"66","author":"Bredemeier","year":"2014","journal-title":"Arthritis Care Res."},{"issue":"8","key":"10.1016\/j.jaut.2015.11.002_bib7","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1136\/annrheumdis-2013-203480","article-title":"Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial","volume":"73","author":"Mariette","year":"2014","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"10.1016\/j.jaut.2015.11.002_bib8","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1136\/annrheumdis-2013-204544","article-title":"An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial","volume":"74","author":"Vital","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.jaut.2015.11.002_bib9","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jaut.2015.11.002_bib10","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1177\/0091270007305297","article-title":"Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response","volume":"47","author":"Breedveld","year":"2007","journal-title":"J.\u00a0Clin. Pharmacol."},{"key":"10.1016\/j.jaut.2015.11.002_bib11","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1002\/art.23902","article-title":"Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis","volume":"58","author":"Dass","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2015.11.002_bib12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jaut.2015.11.002_bib13","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1002\/art.34584","article-title":"Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center","volume":"64","author":"Cartin-Ceba","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2015.11.002_bib14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaut.2014.03.002","article-title":"Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients","volume":"50","author":"Calich","year":"2014","journal-title":"J.\u00a0Autoimmun."},{"issue":"7","key":"10.1016\/j.jaut.2015.11.002_bib15","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/rheumatology\/keu452","article-title":"Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis","volume":"54","author":"Alberici","year":"2015","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.jaut.2015.11.002_bib16","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1002\/art.34583","article-title":"Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Smith","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.jaut.2015.11.002_bib17","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1136\/annrheumdis-2014-206496","article-title":"Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions","volume":"74","author":"Yusof","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.jaut.2015.11.002_bib18","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","article-title":"B\u00a0cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2015.11.002_bib19","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1002\/art.22810","article-title":"Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy","volume":"56","author":"Anolik","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2015.11.002_bib20","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/ard.2007.083162","article-title":"Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus","volume":"67","author":"Albert","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2015.11.002_bib21","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1002\/art.30466","article-title":"B\u00a0cell biomarkers of rituximab responses in systemic lupus erythematosus","volume":"63","author":"Vital","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2015.11.002_bib22","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/art.22400","article-title":"Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis","volume":"56","author":"Vos","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2015.11.002_bib23","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/ard.2007.080960","article-title":"Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response","volume":"67","author":"Thurlings","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2015.11.002_bib24","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1002\/art.22967","article-title":"Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment","volume":"56","author":"Teng","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2015.11.002_bib25","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/art.22603","article-title":"BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of RITUXIMAB-TREATED patients with Sj\u00f6gren\u2019s syndrome","volume":"56","author":"Pers","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2015.11.002_bib26","doi-asserted-by":"crossref","DOI":"10.1186\/ar4359","article-title":"Efficacy and safety of rituximab treatment in early primary Sjogren's syndrome: a prospective, multi-center, follow-up study","volume":"15","author":"Carubbi","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2015.11.002_bib27","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1002\/art.24903","article-title":"Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sj\u00f6gren\u2019s syndrome","volume":"60","author":"Pijpe","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2015.11.002_bib28","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1136\/annrheumdis-2011-201189","article-title":"Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sj\u00f6gren\u2019s syndrome after B cell depletion therapy","volume":"71","author":"Hamza","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2015.11.002_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2015.06.001","article-title":"BAFF-driven autoimmunity requires CD19 expression","volume":"62","author":"Fairfax","year":"2015","journal-title":"J.\u00a0Autoimmun."},{"issue":"2","key":"10.1016\/j.jaut.2015.11.002_bib30","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jbspin.2014.10.018","article-title":"Primary Sj\u00f6gren\u2019s syndrome at a glance today","volume":"82","author":"Youinou","year":"2015","journal-title":"Joint Bone Spine."},{"key":"10.1016\/j.jaut.2015.11.002_bib31","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/ard.62.2.168","article-title":"The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sj\u00f6gren\u2019s syndrome","volume":"62","author":"Mariette","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2015.11.002_bib32","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1196\/annals.1313.004","article-title":"BAFF overexpression is associated with autoantibody production in autoimmune diseases","volume":"1050","author":"Pers","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jaut.2015.11.002_bib33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/art.21478","article-title":"BAFF-induced changes in B cell antigen receptor-containing lipid rafts in Sj\u00f6gren\u2019s syndrome","volume":"54","author":"d\u2019Arbonneau","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2015.11.002_bib34","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/art.22458","article-title":"Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sj\u00f6gren\u2019s syndrome","volume":"56","author":"Daridon","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2015.11.002_bib35","doi-asserted-by":"crossref","first-page":"R51","DOI":"10.1186\/ar1912","article-title":"B\u00a0cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sj\u00f6gren\u2019s syndrome","volume":"8","author":"Ittah","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2015.11.002_bib36","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jaut.2014.02.004","article-title":"Specific forms of BAFF favor BAFF receptor-mediated epithelial cell survival","volume":"51","author":"Lahiri","year":"2014","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.jaut.2015.11.002_bib37","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sj\u00f6gren\u2019s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.jaut.2015.11.002_bib38","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/rheumatology\/keu453","article-title":"Reliability of histopathological salivary gland biopsy assessment in Sj\u00f6gren\u2019s syndrome: a multicentre cohort study","volume":"54","author":"Costa","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaut.2015.11.002_bib39","article-title":"B\u00a0and T cells count in minor salivary glands of primary Sjogren's syndrome: development and validation of a digital procedure","volume":"81","author":"Costa","year":"2015","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.jaut.2015.11.002_bib40","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00277-011-1369-y","article-title":"Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy","volume":"91","author":"Cornec","year":"2012","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.jaut.2015.11.002_bib41","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/ard.2007.079418","article-title":"B\u00a0cell depletion therapy in systemic lupus erythaematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response","volume":"67","author":"Cambridge","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2015.11.002_bib42","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2015.11.002_bib43","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A\u00a0phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2015.11.002_bib44","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sj\u00f6gren\u2019s syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.jaut.2015.11.002_bib45","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/rheumatology\/kev005","article-title":"Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome","volume":"54","author":"Pontarini","year":"2015","journal-title":"Rheumatology (Oxford)."},{"issue":"Suppl.\u00a03","key":"10.1016\/j.jaut.2015.11.002_bib46","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/annrheumdis-2013-eular.318","article-title":"Modification of salivary gland lymphocyte pattern after belimumab in primary Sjogren's syndrome: results of the BELISS study","volume":"72","author":"Seror","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2015.11.002_bib47","first-page":"490","article-title":"Sequential therapy with belimumab followed by rituximab in Sj\u00f6gren\u2019s syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy","volume":"32","author":"De Vita","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"issue":"8","key":"10.1016\/j.jaut.2015.11.002_bib48","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1038\/leu.2015.50","article-title":"Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis","volume":"29","author":"Wild","year":"2015","journal-title":"Leukemia."},{"key":"10.1016\/j.jaut.2015.11.002_bib49","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/art.21650","article-title":"Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: Relationships with B cell depletion, circulating antibodies, and clinical relapse","volume":"54","author":"Cambridge","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2015.11.002_bib50","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/ard.2006.060772","article-title":"Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production","volume":"66","author":"Lavie","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2015.11.002_bib51","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/annrheumdis-2012-202071","article-title":"Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sj\u00f6gren\u2019s syndrome: data from a placebo-controlled clinical trial","volume":"72","author":"Pollard","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2015.11.002_bib52","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.2006.057919","article-title":"Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sj\u00f6gren\u2019s syndrome","volume":"66","author":"Seror","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2015.11.002_bib53","doi-asserted-by":"crossref","first-page":"R167","DOI":"10.1186\/ar2076","article-title":"Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"8","author":"Vallerskog","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2015.11.002_bib54","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/rheumatology\/keu369","article-title":"Belimumab after rituximab as maintenance therapy in lupus nephritis","volume":"53","author":"Kraaij","year":"2014","journal-title":"Rheumatol. Oxf. Engl."},{"issue":"9","key":"10.1016\/j.jaut.2015.11.002_bib55","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1136\/annrheumdis-2015-207499","article-title":"A\u00a0review of salivary gland histopathology in primary Sj\u00f6gren\u2019s syndrome with a focus on its potential as a clinical trials biomarker","volume":"74","author":"Fisher","year":"2015","journal-title":"Ann Rheum Dis."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841115300536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841115300536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:12:33Z","timestamp":1760256753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841115300536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":55,"alternative-id":["S0896841115300536"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2015.11.002","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sj\u00f6gren's syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2015.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}